ArticleMedicine2022
Efficacy and safety of Yinchenwuling Powder for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis of randomized controlled trials.
Article in Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Network-based analysis and experimental validation of identified natural compounds from Yinchen Wuling San for acute myeloid leukemia.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. Owing to the complexity of NAFLD pathogenesis, there is still no specific medication for NAFLD that is safe and effective. Yinchenwuling Powder (YCWLP), a classic Chinese formula, has been widely applied to NAFLD and its efficacy has been proven in numerous studies. However, systematic evaluation of the efficacy and safety of YCWLP for NAFLD is still lacking.
methodsWe will search 8 databases to collect randomized controlled trials of patients with NAFLD treated in the YCWLP from the database inception to September 30, 2022. Two researchers will independently perform the selection of studies, data extraction, and assessment of the risk of bias. The Cochrane Review Manager (RevMan5.4) software will be used for data synthesis and analysis.
resultsComprehensive evidence of YCWLP for the treatment of NAFLD will be provided in this study.
conclusionThe efficacy and safety of YCWLP in treating NAFLD will be proved, providing feasible and effective clinical recommendations for the treatment of NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.